Publications

  1. Zahalka AH, Fram E, Garden E, Howard L, Wiggins E, Babar M, Annam J, Reagan A, Eilender B, de Hoedt A, Freedland SJ, Tewari A, Watts KL. Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance. BJUI Compass. 2024 Oct 9.
  2. Friedrich N, Friedrich N, Janes J, Parrish J, De Hoedt A, Pruett J, Fallick M, Gandhi R, Hong A, Tatonetti N, Freedland S. Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer. Res Sq [Preprint]. 2024 Oct 18.
  3. Kim M, Tamukong P, Galvan GC, Yang Q, De Hoedt A, Freeman MR, You S, Freedland S. Prostate cancers with distinct transcriptional programs in Black and White men. Genome Med. 2024 Jul 23.
  4. Friedrich NA, Gu L, Waller J, De Hoedt AM, Klaassen Z, Freedland SJ. Real-world evidence of 18F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System. Prostate. 2024 Oct.
  5. Gong J, Janes JL, Trustram Eve C, Stock S, Waller J, De Hoedt AM, Kim J, Ghate SR, Shui IM, Freedland SJ. Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer. Cancer. 2024 Nov 15.
  6. Nik-Ahd F, De Hoedt AM, Butler C, Anger JT, Carroll PR, Cooperberg MR, Freedland SJ. Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen. JAMA. 2024 Jul 23.
  7. Bree KK, Janes JL, Hensley PJ, Srinivasan A, De Hoedt AM, Das S, Freedland SJ, Williams SB. Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system. BJU Int. 2024 Apr 29.
  8. Guerrios-Rivera L, Janes JL, De Hoedt AM, Klaassen Z, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ, Fowke JH, Freedland SJ. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH. Cancer Med. 2024 Feb.
  9. Gong J, Kim DM, De Hoedt AM, Bhowmick N, Figlin R, Kim HL, Sandler H, Theodorescu D, Posadas E, Freedland SJ. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?. J Clin Oncol. 2024 Jan 10.
  10. Niino CA, Tholemeier LN, Bresee C, De Hoedt AM, Barbour KE, Kim J, Freedland SJ, Anger JT. Bladder instillation patterns in a cohort of women with interstitial cystitis/bladder pain syndrome. Urogynecology (Phila). 2023 Nov.
  11. Dymanus K, Friedrich NA, Howard LE, Oyekunle T, De Hoedt AM, Labadzhyan A, Polascik T, Klaassen Z, Freedland SJ. Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?-a population-level analysis. Transl Androl Urol. 2023 Oct 31.
  12. Liu IT, Gu L, De Hoedt AM, Cooperberg MR, Amling CL, Kane CJ, Klaassen Z, Terris MK, Guerrios-Rivera L, Vidal AC, Aronson WJ, Freedland SJ, Csizmadi I. Are associations between obesity and prostate cancer outcomes following radical prostatectomy the same in smokers and non-smokers? Results from the SEARCH Cohort. Cancer Causes Control. 2023 Jul 5.
  13. Williams SB, Janes JL, Howard LE, Yang R, De Hoedt AM, Baillargeon JG, Kuo YF, Tyler DS, Terris MK, Freedland SJ. Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans. JAMA Netw Open. 2023 Jun 1.
  14. Cunningham AR, Gu L, Dubinskaya A, De Hoedt AM, Barbour KE, Kim J, Freedland SJ, Anger JT. Quality-of-life impact of interstitial cystitis and other pelvic pain syndromes. Front Pain Res (Lausanne). 2023 May 25.
  15. Sergeyev A, Gu L, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Guerrios-Rivera L, Freedland SJ, Csizmadi I. Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort. Cancer Epidemiol Biomarkers Prev. 2023 Sep 1.
  16. Das S, Gu L, Eve CT, Parrish J, De Hoedt AM, McKee C, Aronson W, Freedland SJ, Williams SB. The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence. Clin Genitourin Cancer. 2023 Apr 28.
  17. Taich L, Zhao H, Stock SR, Howard LE, De Hoedt AM, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urol Pract. 2022 Sep.
  18. Nik-Ahd F, De Hoedt A, Butler C, Anger JT, Carroll PR, Cooperberg MR, Freedland SJ. Prostate Cancer in Transgender Women in the Veterans Affairs Health System, 2000-2022. JAMA. 2023 Jun 6.
  19. Nik-Ahd F, Waller J, De Hoedt AM, Garcia MM, Figueiredo JC, Carroll PR, Cooperberg MR, Freedland SJ. Seeing the unseen: how can we best identify transgender women within the Veterans Affairs healthcare system’s electronic medical record? J Sex Med. 2023 Mar 31.
  20. Janes JL, Boyer MJ, Bennett J, Thomas VM, De Hoedt AM, V DKE, Singla PK, Abran J, Aboushwareb T, Salama JK, Freedland SJ. The 17-Gene Genomic Prostate Score® Test is Prognostic for Outcomes after Primary External Beam Radiation Therapy in Men with Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Jan 1.
  21. Yang R, Zhu D, Howard LE, De Hoedt A, Williams SB, Freedland SJ, Klaassen Z. Identification of Patients With Metastatic Prostate Cancer With Natural Language Processing and Machine Learning. JCO Clin Cancer Inform. 2022 Oct.
  22. Anger JT, Dallas KB, Bresee C, De Hoedt AM, Barbour KE, Hoggatt KJ, Goodman MT, Kim J, Freedland SJ. National prevalence of IC/BPS in women and men utilizing veterans health administration data. Front Pain Res (Lausanne). 2022 Aug 24.
  23. Klaassen Z, Howard L, Wallis CJD, Janes JL, De Hoedt A, Aronson WJ, Polascik TJ, Amling CJ, Kane CJ, Cooperberg MR, Terris MK, Wu Y, Freedland SJ. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)? Prostate Cancer Prostatic Dis. 2022 Sep 1.
  24. Jarman A, Janes JL, Shorter B, Moldwin R, De Hoedt AM, Barbour KE, Kim J, Freedland SJ, Anger JT. Food Sensitivities in a Diverse Nationwide Cohort of Veterans With Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2022 Aug 24.
  25. Dymanus K, Howard LE, Oyekunle T, De Hoedt AM, Labadzhyan A, Polascik T, Freedland SJ, Klaassen Z. Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk? Prostate. 2022 Aug 18.
  26. Neumair M, Kattan MW, Freedland SJ, Haese A, Guerrios-Rivera L, De Hoedt AM, Liss MA, Leach RJ, Boorjian SA, Cooperberg MR, Poyet C, Saba K, Herkommer K, Meissner VH, Vickers AJ, Ankerst DP. Accommodating heterogeneous missing data patterns for prostate cancer risk prediction. BMC Med Res Methodol. 2022 Jul 21.
  27. Anderson EM, Gu L, Oyekunle T, De Hoedt AM, Wiggins E, Gay CJ, Lu DJ, Daskivich TJ, Freedland SJ, Zumsteg ZS, Csizmadi I. Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system. Prostate Cancer Prostatic Dis. 2022 May 26.
  28. You S, Kim M, Widen S, Yu A, Galvan GC, Choi-Kuaea Y, Eyzaguirre EJ, Dyrskjøt L, McConkey DJ, Choi W, Theodorescu D, Chan KS, Shan Y, Tyler DS, De Hoedt AM, Freedland SJ, Williams SB. Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients. Urol Oncol. 2022 May 23.
  29. Tholemeier LN, Bresee C, De Hoedt AM, Barbour KE, Kim J, Freedland SJ, Anger JT. Do medication prescription patterns follow guidelines in a cohort of women with interstitial cystitis/bladder pain syndrome? Neurourol Urodyn. 2022 Jun.
  30. Klaassen Z, Stock S, Waller J, De Hoedt A, Freedland SJ. Association of the COVID-19 Pandemic With Rates of Prostate Cancer Biopsies and Diagnoses in Black vs White US Veterans. JAMA Oncol. 2022 Jun 1.
  31. Dubinskaya A, Tholemeier LN, Erickson T, De Hoedt AM, Barbour KE, Kim J, Freedland SJ, Anger JT. Prevalence of Overactive Bladder Symptoms Among Women With Interstitial Cystitis/Bladder Pain Syndrome. Female Pelvic Med Reconstr Surg. 2022 Mar 1.
  32. Yang R, Zhu D, Howard LE, De Hoedt A, Schroeck FR, Klaassen Z, Freedland SJ, Williams SB. Context-Based Identification of Muscle Invasion Status in Patients With Bladder Cancer Using Natural Language Processing. JCO Clin Cancer Inform. 2022 Jan.
  33. Waller J, Gu L, De Hoedt AM, Freedland SJ, Wang T, Amonkar M, Aurora-Garg D, Liaw KL, Wehn A, Klaassen Z. DNA mismatch repair and microsatellite instability in colorectal tumors: an observational study in the Veterans Affairs Health Care System. Future Oncol. 2022 Feb.
  34. Clements MB, Vertosick EA, Guerrios-Rivera L, De Hoedt AM, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Haese A, Montorsi F, Boorjian SA, Poyet C, Ankerst DP, Vickers AJ. Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. Eur Urol. 2021 Dec 31.
  35. Barlow SK, Oyekunle T, Janes JL, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Klaassen ZW, Terris MK, Freedland SJ, Csizmadi I. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate. 2022 Feb.
  36. Lee MC, Erickson TR, Stock S, Howard LE, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Freedland SJ, Wallis CJD. Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. J Urol. 2022 Mar.
  37. Dallas KB, Bresee C, De Hoedt A, Senechal JF, Barbour KE, Kim J, Freedland SJ, Anger JT. Demographic Differences and Disparities in the Misdiagnosis of Interstitial Cystitis/Bladder Pain Syndrome in a National Cohort of VA Patients. Urology. 2022 May.
  38. Lawler C, Gu L, Howard LE, Branche B, Wiggins E, Srinivasan A, Foster ML, Klaassen Z, De Hoedt AM, Gingrich JR, Theodorescu D, Freedland SJ, Williams SB. The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting. Cancer. 2021 Nov 1.
  39. Kim J, De Hoedt A, Wiggins E, Haywood K, Jin P, Greenwood B, Narain NR, Tolstikov V, Bussberg V, Barbour KE, Kiebish MA, Freedland SJ, Anger JT. Diagnostic Utility of Serum and Urinary Metabolite Analysis in Patients with Interstitial Cystitis/Painful Bladder Syndrome. Urology. 2021 Nov.
  40. Laden BF, Bresee C, De Hoedt A, Dallas KB, Scharfenberg A, Saxena R, Senechal JF, Barbour KE, Kim J, Freedland SJ, Anger JT. Comorbidities in a Nationwide, Heterogenous Population of Veterans with Interstitial Cystitis/Bladder Pain Syndrome. Urology. 2021 Oct.
  41. Williams SB, Howard LE, Foster ML, Klaassen Z, Sieluk J, De Hoedt AM, Freedland SJ. Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System. JAMA Netw Open. 2021 Mar 1.
  42. Zhao H, Howard LE, De Hoedt AM, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. Prostate. 2021 Mar 11.
  43. Yirga A, Oyekunle T, Howard LE, De Hoedt AM, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Klaanssen Z, Freedland SJ, Vidal AC. Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2021 Feb.
  44. Di Bella CM, Howard LE, Oyekunle T, De Hoedt AM, Salama JK, Song H, Freedland SJ, Allott EH. Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy. Prostate. 2020 Oct.
  45.  Vidal AC, Oyekunle T, Howard LE, De Hoedt AM, Kane CJ, Terris MK, Cooperberg MR, Amling CL, Klaassen Z, Freedland SJ, Aronson WJ. Obesity, race, and long-term prostate cancer outcomes. Cancer. 2020 Aug 15.
  46.  Patel DN, Howard LE, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen ZW, Terris MK, Freedland SJ.  Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. Cancer. 2020 Jul 15.
  47. Tolksdorf J, Kattan MW, Boorjian SA, Freedland SJ, Saba K, Poyet C, Guerrios L, De Hoedt A, Liss MA, Leach RJ, Hernandez J, Vertosick E, Vickers AJ, Ankerst DP.  Multi-cohort modeling strategies for scalable globally accessible prostate cancer risk tools. BMC Med Res Methodol. 2019 Oct 15.
  48.  Zhao H, Howard LE, De Hoedt A, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. Racial Discrepancies in Overall Survival among Men Treated with 223Radium. J Urol. 2020 Feb.
  49.  Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2019 Nov 15.
  50. Vidal AC, Howard LE, Wiggins E, De Hoedt AM, Shiao SL, Knott S, Taioli E, Fowke JH, Freedland SJ.Cancer Epidemiol. Natural killer cell activity and prostate cancer risk in veteran men undergoing prostate biopsy. Cancer Epidemiol. 2019 Oct.
  51. Skove SL, Howard LE, Senechal J, De Hoedt A, Bresee C, Cunningham TJ, Barbour KE, Kim J, Freedland SJ, Anger JT. The misdiagnosis of interstitial cystitis/bladder pain syndrome in a VA population. Neurourol Urodyn. 2019 Sep.
  52. Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ. Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. Asian J Urol. 2019 Jul.
  53.  Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer Prostatic Dis. 2019 Dec.
  54.  Vidal AC, Oyekunle T, Howard LE, Shivappa N, De Hoedt A, Figueiredo JC, Taioli E, Fowke JH, Lin PH, Hebert JR, Freedland SJ. Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men. Prostate Cancer Prostatic Dis. 2019 Dec.
  55.  Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB.  MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 Dec.
  56.  Michael J, Oyekunle T, Howard L, De Hoedt A, Hoyo C, Grant D, Freedland S.  Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study. Cancer Causes Control. 2019 Jan.
  57.  Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ.  Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Cancer. 2019 Feb 1.
  58. Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 May.
  59. Michael J, Howard LE, Markt SC, De Hoedt A, Bailey C, Mucci LA, Freedland SJ, Allott EH. Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort. Cancer Prev Res (Phila). 2018 Oct.
  60. Ankerst DP, Straubinger J, Selig K, Guerrios L, De Hoedt A, Hernandez J, Liss MA, Leach RJ, Freedland SJ, Kattan MW, Nam R, Haese A, Montorsi F, Boorjian SA, Cooperberg MR, Poyet C, Vertosick E, Vickers AJ. A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol. 2018 Aug.
  61. Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ. Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. J Urol. 2018 Oct.
  62. Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018 Jun.
  63. Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 Jul.
  64. Grant DJ, Chen Z, Howard LE, Wiggins E, De Hoedt A, Vidal AC, Carney ST, Squires J, Magyar CE, Huang J, Freedland SJ. UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression. BMC Cancer. 2017 Jul 3.
  65. Guerrios-Rivera L, Howard L, Frank J, De Hoedt A, Beverly D, Grant DJ, Hoyo C, Freedland SJ. Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort. Urology. 2017 Jul.
  66. Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 Nov.
  67. Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017 May 1.
  68. Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Divers CH, Valderrama A, Freedland SJ. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer? Prostate Cancer Prostatic Dis. 2016 Dec.
  69. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. 2016 Oct.